Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18363120 | 0.78 | APLNR (0.46) | CYP1A2CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL20919413 | 0.78 | KDM4E (0.32) | CYP1A2CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL16692776 | 0.78 | KDM4E (0.33) | CYP1A2CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL21087260 | 0.77 | NPSR1 (0.43) | CYP1A2CYP3A4CYP2D6ALDH1A1ALOX15 | |
| SCHEMBL614573 | 0.76 | LMNA (0.50) | CYP1A2ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL31539875 | 0.76 | LMNA (0.50) | CYP1A2ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL4049830 | 0.75 | ALDH1A1 (0.46) | ALDH1A1LMNAKDM4ETSHRALOX15 | |
| SCHEMBL1228806 | 0.75 | FFAR1 (0.41) | CYP1A2CYP3A4CYP2D6AKT1KMT2A | |
| SCHEMBL16515478 | 0.74 | GABRA1 (0.38) | CYP1A2CYP3A4CYP2D6ALDH1A1LMNA | |
| SCHEMBL31663320 | 0.73 | DHODH (0.36) | CYP1A2CYP3A4CYP2D6AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340543-A1 | GPR84 ANTAGONISTS AND USES THEREOF | LIMINAL BIOSCIENCES LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| US-12378229-B2 | GPR84 antagonists and uses thereof | Liminal Biosciences Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| WO-2025149628-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024105007-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF | Samsara Therapeutics Inc. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2024-02-29 | — | — | US | disclosed |
| EP-4288430-A1 | GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-12-13 | — | — | EP | disclosed |
| CN-116888116-A | GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255904-A2 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| US-20230192677-A1 | CYP11A1 INHIBITORS | ORION CORPORATION (FI) | 2023-06-22 | — | — | US | disclosed |
| EP-2142555-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625891-B2 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2009048547-A1 | DIPHENYL SUBSTITUTED CYCLOALKANES | MERCK & CO., INC. (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-2013174-A2 | DIARYL SUBSTITUTED ALKANES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008119663-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249087-A1 | Heterocylic antiviral compounds | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192677-A1 | CYP11A1 INHIBITORS | CYP11B1, CYP11B2, CYP17A1 | CYP1A2 34/4885CYP3A4 61/4885CYP2D6 67/4885 |
| US-12378229-B2 | GPR84 antagonists and uses thereof | GPR84, GPR88, GPR65 | CYP1A2 2157/4885CYP3A4 1841/4885CYP2D6 2858/4885 |
| US-20080249087-A1 | Heterocylic antiviral compounds | CCR5, CCR1, CXCR1 | CYP1A2 389/4885CYP3A4 340/4885CYP2D6 1009/4885 |
| US-20240066027-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | CYP1A2 176/4885CYP3A4 872/4885CYP2D6 847/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | CYP1A2 301/4885CYP3A4 951/4885CYP2D6 616/4885 |
| US-20250340543-A1 | GPR84 ANTAGONISTS AND USES THEREOF | GPR84, GPR88, GPR65 | CYP1A2 2157/4885CYP3A4 1841/4885CYP2D6 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.